Reven, LLC
600 Corporate Circle, Ste D
Golden, CO 80401 – USA

FOR IMMEDIATE RELEASE

Reven Announces the Appointment of Dr. James Carlson as Executive Vice President of Development

Golden, Colorado, Friday, January 8, 2019 1:00am MDT – Reven, LLC, a biopharmaceutical company that is developing Rejuveinix (RJX) for patients with cardiovascular and other health conditions, announced today that Dr. James Carlson has been appointed to the position of Executive Vice President of Development.

"We have hired Dr. James Carlson as Executive Vice President of Development. Carlson will be responsible for all development activities for the Reven group including regulatory, clinical research and in an interface capacity with the Food & Drug Administration (FDA). The Board of Directors welcome Carlson to the Reven team." said Michael Volk, Chief Financial Officer.

Prior to his position as CEO and co-founder of PRACS Institute, Ltd., a company that tests new and developing types of medicine, Carlson held a pharmacology professorship at North Dakota State University. He is a Senior Managing Partner at Retain Pharmacy Solutions, the President and Chief Executive Officer of Algorithme Pharma and Chief Scientific Officer for AXIS Clinicals USA, a clinical research provider. Carlson holds a Pharm.D. in Clinical Pharmacy from the University of Michigan and a B.Sc. in Pharmacy from the University of Iowa.

"I am very grateful to have the opportunity to share my experience in the organization of business operations, workflow and creating overall efficiencies including electronic data capture in clinical trials. Instilling team responsibility and ownership of operations are key to success in company development, growth and the quality of outcomes," said Carlson.

Carlson will leverage his expertise leading multiple functional and executive areas across several industries in Reven's continuing development of RJX. As Reven finalizes its Phase 1 study for RJX, Carlson will be instrumental in preparing the Phase 2 clinical trial while expediting the approval process in all upcoming development stages towards commercialization.

"At Reven, we are constantly discovering and innovating to make a meaningful impact for the patients we serve. We are pushing the boundaries on what science and technology can do, making the impossible, possible. Dr. Carlson's commitment to excellence in clinical research is a perfect match for our efforts at Reven," said Peter Lange, Founder and CEO.

About Cardiovascular Disease

Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular disease includes coronary artery diseases such as angina and myocardial infarction. Other CVDs include stroke, heart failure, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease and more. Cardiovascular diseases are the leading cause of death globally, of which coronary artery disease and stroke account for 80% of CVD deaths in males and 75% of CVD deaths in females. In the United States, 11% of people between 20 and 40

have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD.

About Reven, LLC

Reven, LLC is a Golden, Colorado based biopharmaceutical company. Reven's vision is to make a difference in the world by making its products accessible to everyone suffering the effects of cardiovascular disease. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, RJX, targets Critical Limb Ischemia patients facing amputation as well as a larger patient population suffering PAD and other vascular related medical conditions.

Forward-Looking Statements

This announcement may contain forward-looking statements. These statements are based on Reven management's current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those indicated or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with our ability to continue to operate as a going concern; our ability to raise sufficient additional funds to continue operations and to conduct clinical trials of RJX in the United States and elsewhere; our ability to enlist clinical trial sites and enroll patients; the risk that the FDA stops RJX early as a result of the occurrence of certain safety events or does not approve an expansion of RJX; obtaining and maintaining regulatory approvals required to market and sell our products; the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to assumptions regarding the size of the available market; the benefits of our products; product pricing; timing of product launches; future financial results; and other factors. Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.

Contact: Vincent Vanderbent
Director of Corporate Communications
Reven, LLC
+1 425.305.9547
vincent.vanderbent@reven.com
600 Corporate Circle, Suite D
Golden, CO 80401, USA

Reven, LLC
600 Corporate Circle, Ste D
Golden, CO 80401 – USA

###